Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit.
Arianna Miles-JayEvan S SnitkinMichael Y LinTeppei ShimasakiMichael E SchoenyChristine FukudaThelma DanganaNicholas M MooreSarah E SansomRachel D YelinPamela BellKrishna RaoMicah KeidanAlexandra StandkeChristine BassisMary K HaydenVincent B YoungPublished in: Nature medicine (2023)
Despite enhanced infection prevention efforts, Clostridioides difficile remains the leading cause of healthcare-associated infections in the United States. Current prevention strategies are limited by their failure to account for patients who carry C. difficile asymptomatically, who may act as hidden reservoirs transmitting infections to other patients. To improve the understanding of asymptomatic carriers' contribution to C. difficile spread, we conducted admission and daily longitudinal culture-based screening for C. difficile in a US-based intensive care unit over nine months and performed whole-genome sequencing on all recovered isolates. Despite a high burden of carriage, with 9.3% of admissions having toxigenic C. difficile detected in at least one sample, only 1% of patients culturing negative on admission to the unit acquired C. difficile via cross-transmission. While patients who carried toxigenic C. difficile on admission posed minimal risk to others, they themselves had a 24-times greater risk for developing a healthcare-onset C. difficile infection than noncarriers. Together, these findings suggest that current infection prevention practices can be effective in preventing nosocomial cross-transmission of C. difficile, and that decreasing C. difficile infections in hospitals further will require interventions targeting the transition from asymptomatic carriage to infection.
Keyphrases
- clostridium difficile
- healthcare
- intensive care unit
- emergency department
- ejection fraction
- newly diagnosed
- primary care
- physical activity
- prognostic factors
- escherichia coli
- drug delivery
- patient reported outcomes
- copy number
- cancer therapy
- health information
- staphylococcus aureus
- health insurance
- acinetobacter baumannii
- quality improvement
- genome wide